Icilio Cavero
232 works · 5,878 citations · h-index 42
Top works
- The potassium channel opener cromakalim (BRL 34915) activates ATP-dependent K+ channels in isolated cardiac myocytes
- Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning.
- QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development
- Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-Δ9-trans-tetrahydrocannabinol
- Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents.
- Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias
- Potassium channel openers act through an activation of ATP-sensitive K+ channels in guinea-pig cardiac myocytes
- The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes.
- The pharmacology of prazosin, a novel antihypertensive agent
- Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
- Nicorandil Attenuates Myocardial Dysfunction Associated with Transient Ischemia by Opening ATP-Dependent Potassium Channels
- K+ channel openers and ‘natural’ cardioprotection
- Studies on the mechanism of the vasodilator effects of prazosin in dogs and rabbits
- Effects of Prazosin and Phentolamine on Cardiac Presynaptic α-Adrenoceptors in the Cat, Dog and Rat
- Preliminary studies on SL 75212, a new potent cardioselective beta-adrenoceptor antagonist [proceedings].
- Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents
- Differential effects of prazosin on the pre- and postsynaptic alpha-adrenoceptors in the rat and dog [proceedings].
- 2-(3-Pyridyl)-tetrahydrothiopyran-2-carbothioamide derivatives and analogues: A novel family of potent potassium channel openers
- Synthesis of a series of compounds related to betaxolol, a new .beta.1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases
- Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties